Follow RSS for latest reports on this topicAlzumab (Itolizumab) - Market Research and Reports

Biocon Launches ALZUMAb™ - a ‘First in Class’ Novel Biologic Treatment for Psoriasis Patients in India

• ALZUMAb™-World's first novel anti-CD6 antibody developed by Biocon to address a large unmet need for the treatment of Psoriasis in India
• Excellent safety and efficacy profile with very low opportunistic infection rates and longer remission period
• Offers a new treatment option for Psoriasis with a less aggressive dosing regimen and a longer treatment free period, ensuring better patient compliance and convenience
• Is an innovative affordable treatment option with a promise to offer a better quality of life for the patient
• Will provide an effective biologic treatment solution to 1-2% of Indian population suffering from Psoriasis

• ALZUMAb™- (Itolizumab) has demonstrated preclinical and/clinical evidence in treating other autoimmune diseases like rheumatoid arthritis, psoriatic arthritis and multiple sclerosis.
• Biocon is committed to offering this novel anti -CD6 biologic from India to patients across the globe

Biocon, Asia's premier biotechnology company, in August 2013 announced the launch of its ‘first in class’ novel biologic ALZUMAb™ (Itolizumab), the world’s first anti-CD6 monoclonal antibody to be introduced for treating patients with chronic plaque psoriasis, in India.
ALZUMAb™ with a unique Mechanism of Action (MOA) offers superior safety and similar efficacy profile compared to other existing therapies, and has a long remission period with very low opportunistic infection rate. Psoriasis is a socially debilitating disease affecting 2-3 % of world population. The global Psoriasis market size is estimated to cross $8 bn by 2016.

Product information: http://www.biocon.com/biocon_products_bio_BF_alzumab.asp?subLink=news&Fileid=478

BioPortfolio's Easy Ordering System

  1. Search for the report you need from our store
  2. Make online payment with our easy checkout process
  3. Receive PDF report via email

Easy Online Payment or Pro Forma Invoice

We accept the following credit cards...



or can supply a pro-forma invoice if required.

Related Reports:

Additional Searches

You may also like to search separately for: Alzumab (Itolizumab)

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data
{STICKYFOOTERMOBILE}